|Bid||0.00 x 1100|
|Ask||0.00 x 800|
|Day's Range||105.46 - 107.14|
|52 Week Range||62.55 - 113.41|
|Beta (5Y Monthly)||0.81|
|PE Ratio (TTM)||39.23|
|Earnings Date||Apr 29, 2021 - May 03, 2021|
|Forward Dividend & Yield||5.20 (4.82%)|
|Ex-Dividend Date||Apr 14, 2021|
|1y Target Est||121.80|
AbbVie stock was within a buy zone in mid-February after the company topped fourth-quarter views and issued upbeat 2021 guidance. The company also has the option to buy Cypris Medical.
AbbVie Inc (NYSE: ABBV) has landed an option to buy Mitokinin upon completing IND-enabling studies on the latter's lead PINK1 compound for Parkinson's disease. Mitokinin's novel PINK1 compounds selectively increase the activity of PINK1, a master regulator of mitochondrial quality control that is genetically linked to Parkinson's disease. Mitokinin is based on technology discovered by Nicholas Hertz, Ph.D., and Kevan Shokat, Ph.D., at the University of California, San Francisco. Now, AbbVie has signed up to help Mitokinin get to the next stage in its evolution. In return for the option to buy Mitokinin, AbbVie is making an upfront payment. Price Action: ABBV shares are up 0.1% at $108.5 in market trading hours on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaAbbVie's Allergan Files US Application AGN-190584 For PresbyopiaAbbVie's Humira Gets FDA Approval For Pediatric Ulcerative Colitis© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Buffett's Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) added AbbVie (NYSE: ABBV) to its portfolio in the third quarter of last year. What makes AbbVie so appealing to two very different investors like Buffett and Wood? It's pretty easy to figure out why Wood chose AbbVie for the ARK Genomic Revolution ETF.